Singular Health Group (ASX:SHG) completes cranial implant design project – The Market Herald

Subscribe to

Be the first with the news that moves the market

  • Singular Health Group (SHG) has completed its Cranial Implant Design project
  • After developing and integrating an artificial intelligence model capable of automatically generating a cranial implant in four minutes with 91 percent accuracy, SHG plans to work with Osteopore to validate the model and receive a U.S. FDA and apply for Australian TGA certification
  • The company says it looks forward to working closely with Osteopore to develop a commercial outcome for both companies
  • Singular Health Group is up 2.44 percent and trades at 21 cents, while Osteopore is up 2.78 percent and trades at 18.5 cents

Singular Health Group (SHG), in collaboration with Australia’s national science agency CSIRO, has completed its Cranial Implant Design project.

After developing and integrating an artificial intelligence model capable of automatically generating a cranial implant in four minutes with 91 percent accuracy, SHG said it is looking to collaborate with Osteopore (OSX) to develop the model to validate and apply for US FDA Australia TGA certification.

Osteopore is recognized as a world leader in the manufacture of innovative regenerative implants on a commercial scale. In collaboration with clinicians and researchers, Osteopore develops implants that address unmet clinical needs, improve patient outcomes, improve lives and potentially reduce healthcare costs.

SHG previously finalized its AI model, which was configured to use standard DICOM inputs to work on both Windows and macOS hardware and output the generated cranial implant design into the company’s 3Dicom Surgical software.

The project was made possible by CSIRO Kick-Start, which provides funding and support to Australian start-ups and small businesses to access CSIRO’s research expertise and capabilities to grow and develop their businesses.

In 3Dicom Surgical, the cranial implant can be edited in either 2D or 3D view by a surgeon or bioengineer to make patient-specific changes and increase accuracy to close to 100 percent.

The primary goal of SHG’s new project with Osteopore would be to gather empirical data to develop a route to full FDA clearance for the AI ​​model and deployment for use with Osteopore’s state-of-the-art bioresorbable material.

“I have to commend the innovative development and work ethic of the CSIRO team,” said Thomas Hanly, Chief Executive Officer of Singular Health.

“This top-of-the-line model truly demonstrates the ability of AI to accelerate the manual processes in the scan-to-surgery workflow compared to the AutoImplant Grand Challenge 2021.

“I now look forward to working closely with Osteopore to develop a commercial outcome for both companies.”

Singular Health Group was up 2.44 percent and traded at 21 cents, while Osteopore was up 2.78 percent and traded at 18.5 cents.

Comments are closed.